top of page
Search

Steris (STE)

  • Writer: Abacus Research
    Abacus Research
  • Nov 26, 2019
  • 1 min read

Steris is a high quality sterilisation business, with ~6.5% sustainable organic growth due to pricing power and volume growth. Regarding business positioning, there is little not to like. 


We would argue that Steris has all the markings of compounder, and has got to the point where the balance sheet has delevered and synergies have run out, therefore a deal or share buy backs should be on the cards. 


Ethylene Oxide is causing a lot of concern, however we are unconcerned by the EPA's focus as we do not see Ethylene Oxide as a risk for Steris.  Unfortunately, as for many other defensives, we find the risk reward balanced. 


Potential Upside: $174(+16%)

Sensible Downside: $122(-20%)


 
 
 

Recent Posts

See All
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 
Figure (FIGR)

We believe Figure is highly disruptive. If tokenisation of real-world assets is a theme for the next decade, FIGR could be at the centre of it. Figure has found a real-world use for blockchain, provin

 
 
 

Comments

bottom of page